يعرض 1,161 - 1,180 نتائج من 21,342 نتيجة بحث عن '(( significant decrease decrease ) OR ( significant rates decrease ))*', وقت الاستعلام: 0.52s تنقيح النتائج
  1. 1161
  2. 1162
  3. 1163
  4. 1164
  5. 1165

    Study Data. حسب Jonathan S. Jahr (2709088)

    منشور في 2025
    "…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …"
  6. 1166

    Study outcomes. حسب Jonathan S. Jahr (2709088)

    منشور في 2025
    "…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …"
  7. 1167

    Patient characteristics. حسب Jonathan S. Jahr (2709088)

    منشور في 2025
    "…A total of 103 subjects were evaluated, of whom 38 received intravenous dexamethasone (either 4 mg, 8 mg, or 10 mg) during their anesthetic course and 65 patients had not received dexamethasone. The average heart rate (HR) slowing (3.2 bpm ± 3.9 in the control group, 3.7 bpm ± 3.8 in the dexamethasone group), and maximal HR slowing (5.0 bpm ± 3.9 in the control group, 5.0 bpm ± 3.8 in the dexamethasone group) over the five minutes following sugammadex administration were not significant between groups (average HR slowing p = 0.553, maximal HR slowing p = 0.988). …"
  8. 1168
  9. 1169
  10. 1170

    Gene set enrichment analysis (GSEA) of the DEGs. حسب Wei He (131453)

    منشور في 2025
    الموضوعات:
  11. 1171

    SWFT scores and Lactate Levels. حسب Burhan Demirkıran (21601740)

    منشور في 2025
    الموضوعات:
  12. 1172

    HRV Values. حسب Burhan Demirkıran (21601740)

    منشور في 2025
    الموضوعات:
  13. 1173

    HRV values (Approximately here). حسب Burhan Demirkıran (21601740)

    منشور في 2025
    الموضوعات:
  14. 1174

    Trial Design (Approximately Here). حسب Burhan Demirkıran (21601740)

    منشور في 2025
    الموضوعات:
  15. 1175

    Supplementary Figure. حسب Burhan Demirkıran (21601740)

    منشور في 2025
    الموضوعات:
  16. 1176
  17. 1177
  18. 1178
  19. 1179
  20. 1180